1.07 USD
+0.03 (+2.88%)
1.04 USD
-0.03 (-2.8%)
We assign a fundamental rating of 2 out of 10 to YCBD. YCBD was compared to 190 industry peers in the Pharmaceuticals industry. While YCBD seems to be doing ok healthwise, there are quite some concerns on its profitability. YCBD has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- YCBD had negative earnings in the past year.
- In the past year YCBD has reported a negative cash flow from operations.
- YCBD had negative earnings in each of the past 5 years.
- YCBD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- With a Return On Assets value of -41.99%, YCBD perfoms like the industry average, outperforming 42.63% of the companies in the same industry.
- With a Return On Equity value of -60.55%, YCBD perfoms like the industry average, outperforming 47.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.99% | ||
| ROE | -60.55% | ||
| ROIC | N/A |
ROA(3y)-93.71%
ROA(5y)-96.7%
ROE(3y)-250.41%
ROE(5y)-202.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- YCBD has a better Gross Margin (62.37%) than 71.58% of its industry peers.
- YCBD's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for YCBD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.19%
2. Health
2.1 Basic Checks
- YCBD does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, YCBD has more shares outstanding
- The number of shares outstanding for YCBD has been increased compared to 5 years ago.
- YCBD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- YCBD has an Altman-Z score of -20.77. This is a bad value and indicates that YCBD is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of YCBD (-20.77) is worse than 84.74% of its industry peers.
- YCBD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.77 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
- YCBD has a Current Ratio of 2.05. This indicates that YCBD is financially healthy and has no problem in meeting its short term obligations.
- YCBD has a worse Current ratio (2.05) than 61.05% of its industry peers.
- YCBD has a Quick Ratio of 1.20. This is a normal value and indicates that YCBD is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.20, YCBD is not doing good in the industry: 74.74% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.05 | ||
| Quick Ratio | 1.2 |
3. Growth
3.1 Past
- YCBD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.81%, which is quite impressive.
- Looking at the last year, YCBD shows a decrease in Revenue. The Revenue has decreased by -1.50% in the last year.
- Measured over the past years, YCBD shows a very negative growth in Revenue. The Revenue has been decreasing by -14.45% on average per year.
EPS 1Y (TTM)70.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.13%
Revenue 1Y (TTM)-1.5%
Revenue growth 3Y-18.46%
Revenue growth 5Y-14.45%
Sales Q2Q%3.59%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.95%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- YCBD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year YCBD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for YCBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.07
+0.03 (+2.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-19 2025-12-19/amc
Earnings (Next)02-11 2026-02-11
Inst Owners4.63%
Inst Owner Change0%
Ins Owners6.34%
Ins Owner Change30.68%
Market Cap9.53M
Revenue(TTM)19.19M
Net Income(TTM)-4.38M
Analysts82.86
Price Target2.04 (90.65%)
Short Float %56.48%
Short Ratio0.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-533.75%
Min EPS beat(2)-929.41%
Max EPS beat(2)-138.09%
EPS beat(4)1
Avg EPS beat(4)-260.56%
Min EPS beat(4)-929.41%
Max EPS beat(4)41.71%
EPS beat(8)4
Avg EPS beat(8)-111.36%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-8.21%
Min Revenue beat(2)-14.83%
Max Revenue beat(2)-1.58%
Revenue beat(4)0
Avg Revenue beat(4)-7.3%
Min Revenue beat(4)-14.83%
Max Revenue beat(4)-1.58%
Revenue beat(8)1
Avg Revenue beat(8)-7.88%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-20%
EPS NQ rev (3m)-20%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-8.21%
Revenue NQ rev (3m)-8.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.5 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.32 | ||
| P/tB | 1.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.04
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS2.15
BVpS0.81
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.99% | ||
| ROE | -60.55% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.37% | ||
| FCFM | N/A |
ROA(3y)-93.71%
ROA(5y)-96.7%
ROE(3y)-250.41%
ROE(5y)-202.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.19%
F-Score6
Asset Turnover1.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 16.36% | ||
| Cap/Sales | 0.96% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.05 | ||
| Quick Ratio | 1.2 | ||
| Altman-Z | -20.77 |
F-Score6
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)19.37%
Cap/Depr(5y)25.83%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.13%
EPS Next Y94.95%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.5%
Revenue growth 3Y-18.46%
Revenue growth 5Y-14.45%
Sales Q2Q%3.59%
Revenue Next Year4.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-154.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-311.68%
OCF growth 3YN/A
OCF growth 5YN/A
CBDMD INC / YCBD FAQ
What is the ChartMill fundamental rating of CBDMD INC (YCBD) stock?
ChartMill assigns a fundamental rating of 2 / 10 to YCBD.
What is the valuation status of CBDMD INC (YCBD) stock?
ChartMill assigns a valuation rating of 0 / 10 to CBDMD INC (YCBD). This can be considered as Overvalued.
How profitable is CBDMD INC (YCBD) stock?
CBDMD INC (YCBD) has a profitability rating of 1 / 10.
How sustainable is the dividend of CBDMD INC (YCBD) stock?
The dividend rating of CBDMD INC (YCBD) is 0 / 10 and the dividend payout ratio is 0%.